Canada Markets open in 5 hrs 28 mins

Awakn Life Sciences Corp. (AWKN.NE)

NEO - NEO Real Time Price. Currency in CAD
Add to watchlist
0.4600-0.0600 (-11.54%)
At close: 01:39PM EDT
Full screen
Previous Close0.5200
Open0.5100
Bid0.4600 x N/A
Ask0.6000 x N/A
Day's Range0.4600 - 0.5100
52 Week Range0.4400 - 3.3500
Volume6,257
Avg. Volume22,276
Market Cap11.358M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.6460
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
  • Market Exclusive

    Weekly Roundup on the Cannabis Sector & Psychedelic Sector

    Key Takeaways; Cannabis Sector High Tide’s third-quarter revenue rose 18% to C$95.4 million; in addition, the company closed a $19 million non-dilutive credit arrangement. Key Takeaways; Psychedelic Sector Cybin announced key research and development milestones, beating anticipated timeframe. Awakn reported strong Q2 earnings. The company also announced participation in a global investment conference. This week, […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared fir

  • Newsfile

    Awakn Life Sciences Reports Strong Q2 2022 Results

    Awakn delivered revenue growth of 34% in Q2Awakn also announces closing of first tranche of private placement financingToronto, Ontario--(Newsfile Corp. - September 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today its financial results and business highlights for the three months ended Jul

  • Newsfile

    Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis(R) Technology (An Orally Disintegrating Tablet) to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program

    Toronto, Ontario--(Newsfile Corp. - September 12, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), today announces it has signed a drug development agreement with Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and